The respiratory microbiota: associations with influenza symptomatology and viral shedding.
Adolescent
Adult
Antiviral Agents
/ therapeutic use
Child
Child, Preschool
Family Characteristics
Female
Humans
Infant
Influenza, Human
/ drug therapy
Male
Microbiota
/ physiology
Nicaragua
Nose
/ microbiology
Oseltamivir
/ therapeutic use
Pharynx
/ microbiology
Real-Time Polymerase Chain Reaction
Smoking
Virus Shedding
/ physiology
Young Adult
Influenza
Microbiota
Signs and symptoms
Virus shedding
Journal
Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
17
01
2019
revised:
06
06
2019
accepted:
24
07
2019
pubmed:
28
8
2019
medline:
24
9
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Manifestations of infection and the degree of influenza virus vary. We hypothesized that the nose/throat microbiota modifies the duration of influenza symptoms and viral shedding. Exploring these relationships may help identify additional methods for reducing influenza severity and transmission. Using a household transmission study in Nicaragua, we identified secondary cases of influenza virus infection, defined as contacts with detectable virus or a greater than 4-fold change in hemagglutinin inhibition antibody titer. We characterized the nose/throat microbiota of secondary cases before infection and explored whether the duration of symptoms and shedding differed by bacterial community characteristics. Among 124 secondary cases of influenza, higher bacterial community diversity before infection was associated with longer shedding duration (Shannon acceleration factor [AF]: 1.61, 95% confidence interval [CI]: 1.24, 2.10) and earlier time to infection (Shannon AF: 0.72, 95% CI: 0.53, 0.97; Chao1 AF: 0.992, 95% CI: 0.986, 0.998). Neisseria and multiple other oligotypes were significantly associated with symptom and shedding durations and time to infection. The nose/throat microbiota before influenza virus infection was associated with influenza symptoms and shedding durations. Further studies are needed to determine if the nose/throat microbiota is a viable target for reducing influenza symptoms and transmission.
Identifiants
pubmed: 31451313
pii: S1047-2797(19)30040-7
doi: 10.1016/j.annepidem.2019.07.013
pmc: PMC6755049
mid: NIHMS1536229
pii:
doi:
Substances chimiques
Antiviral Agents
0
Oseltamivir
20O93L6F9H
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-56.e6Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120997
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI119463
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI088654
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Vaccine. 2000 Mar 17;18(18):1910-9
pubmed: 10699340
Nature. 2005 Sep 8;437(7056):209-14
pubmed: 16079797
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Epidemiology. 2009 May;20(3):344-7
pubmed: 19279492
N Engl J Med. 2009 Jun 18;360(25):2605-15
pubmed: 19423869
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068
N Engl J Med. 2010 Jun 10;362(23):2175-2184
pubmed: 20558368
Database (Oxford). 2010 Jul 06;2010:baq013
pubmed: 20624719
Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9
pubmed: 21402903
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
J Exp Med. 2012 Feb 13;209(2):251-8
pubmed: 22291094
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
PLoS One. 2012;7(2):e30126
pubmed: 22319561
Immunity. 2012 Jul 27;37(1):158-70
pubmed: 22705104
J Infect Dis. 2012 Oct 1;206(7):1078-84
pubmed: 22837493
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
J Allergy Clin Immunol. 2014 Feb;133(2):405-13
pubmed: 24131826
ISME J. 2015 Mar 17;9(4):968-79
pubmed: 25325381
Gut. 2016 Apr;65(4):575-83
pubmed: 26511795
Pediatr Infect Dis J. 2016 May;35(5):583-6
pubmed: 26910589
Clin Infect Dis. 2017 Mar 15;64(6):736-742
pubmed: 28011603
Nature. 2017 Aug 24;548(7668):407-412
pubmed: 28813414
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
PLoS One. 2019 Jan 9;14(1):e0207898
pubmed: 30625134